OBI announces OBI-833 termination and refocuses resources on ADC development

Date of occurrence of the event:2025/05/12 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office Reciprocal shareholding ratios: NA Cause of occurrence: The Company’s Board of Directors has determined to terminate the development and Phase II clinical trial of OBI-833 and to redirect its resources to focus on […]